Fig 1: Dynamics of SMAD signaling in living cells(A) Nuc/cyt YFP-SMAD1 ratios for selected cells upon stimulation with 1 ng/mL BMP9.(B) Median nuc/cyt SMAD1 ratio in cell populations upon stimulation with 1 ng/mL BMP9 in fresh medium containing 1.5% FBS (blue), cells treated with fresh medium containing 1.5% FBS only (dark gray), or in unstimulated control populations (light gray). Solid lines represent median values; shaded areas indicate 25th to 75th percentiles.(C) Median nuc/cyt SMAD1 ratio following stimulation with indicated BMP9 concentrations.(D) Normalized SMAD1 response to increasing doses of BMP9 based on peak median nuc/cyt SMAD1 ratios. The half-maximal effective concentration (EC50 value) was calculated from the indicated fit (blue line and orange circle). Data represent mean ± SD from three independent experiments.(E) Peak nuc/cyt SMAD1 ratio in cells treated with various ALK1i (K02288) concentrations 1 h before stimulation with 1 ng/mL BMP9. Boxes include data between the 25th and 75th percentiles of the cell population, black lines indicate the median and whiskers extend to maximum values within 1.5× the interquartile range. Notches indicate 95% confidence intervals. Dashed line serves as guide to the eye.(F) Normalized SMAD1 response to increasing concentrations of ALK1i based on peak nuc/cyt SMAD1 ratios upon stimulation with 1 ng/ml BMP9. The half-maximal inhibitory concentration (IC50 value) was calculated from the indicated fit (blue line and orange circle). Data represent mean ± SD from three independent experiments.(G) ALK1 inhibitor efficacy at different timepoints relative to BMP9 induction. Cells were treated with 1 μM ALK1i 1 h before or 1.5, 3, 5 h after 1 ng/mL BMP9 stimulation. Lines indicate median nuc/cyt SMAD1 ratio in cell populations.(H) Time required to reduce nuc/cyt ratio from 90% to 10% for SMAD1 (lilac), SMAD5 (blue), and SMAD9 (green) upon 1 μM ALK1i addition at 1.5, 3, or 5 h after BMP9 stimulation. Symbols represent individual biological replicates; lines represent the mean.For all experiments, cells were pre-cultured in 1.5% FBS medium for 20 h prior to stimulation. Time-lapse imaging was performed every 10 min for 16 h, starting 0.5 h before stimulation, unless otherwise stated. See Table S1 for number cells analyzed in this and subsequent figures. Data are representative for at least three biological repeats if not stated otherwise.
Fig 2: Differential SMAD activation affects downstream gene expression and cellular motility(A and B) RT-qPCR analysis of (A) DLL4 and (B) ID2 expression in SMAD1 reporter cells 1.5 h after stimulation with BMP9 (1 ng/mL) or BMP7 (250 ng/mL). Where indicated, FKBP12 PROTAC (200 nM) was added 24 h before stimulation. β-Actin served as internal control. Error bars represent standard deviation of technical triplicates. Data are representative for two biological repeats.(C) Quantification of motility in individual cells following treatment with BMP9 (1 ng/mL) or BMP7 (250 ng/mL). Cells were followed for 48 h by time-lapse microscopy and their cumulative displacement quantified. PROTAC (200 nM) was added 24 h and ALK1i (1 μM) or Alk5/4i (10 μM) were added 1 h before stimulation where indicated. See Figure S12 for replicate data.Cells were cultured in 1.5% FBS medium with or without PROTAC for 24 h. Data are representative for two biological repeats.
Supplier Page from Sino Biological, Inc. for Human Smad1 Gene ORF cDNA clone in cloning vector